The purpose of this study is to compare the effects of the study drug, obicetrapib when administered together with the drug ezetimibe as a fixed dose combination. A fixed dose combination means the two drugs are combined into a single tablet. The study will also check how safe obicetrapib and ezetimibe is for participants with high levels of LDL-C in the blood.
Contact phone
Sparrow Clinical Research Institute | 517.364.5760
Contact email
scri@sparrow.org
Principal investigator
Dr. David Strobl, DO
Trial Category
Heart & Vascular
Trial SubCategory
Lipid Management; Cardiovascular Disease
Webform